<SEC-DOCUMENT>0001193125-14-080635.txt : 20140303
<SEC-HEADER>0001193125-14-080635.hdr.sgml : 20140303
<ACCEPTANCE-DATETIME>20140303172710
ACCESSION NUMBER:		0001193125-14-080635
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20140303
DATE AS OF CHANGE:		20140303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		14661625

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d686794d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement No. 17</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(to
Prospectus dated May&nbsp;30, 2013)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424 (b)(4)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-187508</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686794g45p43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;), by that certain Prospectus Supplement No.&nbsp;11 dated November&nbsp;21, 2013
(&#147;Supplement No.&nbsp;11&#148;), by that certain Prospectus Supplement No.&nbsp;12 dated December&nbsp;5, 2013 (&#147;Supplement No.&nbsp;12&#148;), by that certain Prospectus Supplement No.&nbsp;13 dated January&nbsp;8, 2014 (&#147;Supplement
No.&nbsp;13&#148;), by that certain Prospectus Supplement No.&nbsp;14 dated February&nbsp;10, 2014 (&#147;Supplement No.&nbsp;14&#148;), by that certain Prospectus Supplement No.&nbsp;15 dated February&nbsp;12, 2014 (&#147;Supplement
No.&nbsp;15&#148;), and by that certain Prospectus Supplement No.&nbsp;16 dated February&nbsp;18, 2014 (&#147;Supplement No.&nbsp;16&#148;, and together with Supplement No.&nbsp;1, Supplement No.&nbsp;2, Supplement No.&nbsp;3, Supplement No.&nbsp;4,
Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, Supplement No.&nbsp;9, Supplement No.&nbsp;10, Supplement No.&nbsp;11, Supplement No.&nbsp;12, Supplement No.&nbsp;13, Supplement No.&nbsp;14, and Supplement
No.&nbsp;15, the &#147;Supplements&#148;), which form a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the
Supplements with the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on March&nbsp;3, 2014 (the &#147;Current Report&#148;). Accordingly, we have attached the
Current Report to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale
of up to 125,000 shares of Series A Convertible Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of
Common Stock underlying the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements.
This prospectus supplement updates and supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the
information in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol
&#147;ABIO.&#148; On March&nbsp;3, 2014, the last reported sale price of our common stock was $1.85 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our
securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 23 of our quarterly report on Form
10-Q for the quarterly period ended September&nbsp;30, 2013 before you decide whether to invest in shares of our common stock. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is March&nbsp;3, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): March&nbsp;3, 2014 (February 27, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bonuses, Base Salaries and Equity Grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2014, the Compensation Committee (the &#147;<B>Committee</B>&#148;) of the Board of Directors of ARCA biopharma, Inc. (the
&#147;<B>Company</B>&#148;), approved cash bonuses (the &#147;<B>Bonuses</B>&#148;) for each of the executive officers of the Company in the amounts set forth below, payable on or around March&nbsp;7, 2014. The Committee also approved the base
salaries for the Company&#146;s &#147;named executive officers&#148; (as defined in Item&nbsp;402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), in each case as set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name and Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B><br><B>Cash&nbsp;Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">60,050</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">281,139</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick M. Wheeler</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">46,650</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">268,975</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. Ozeroff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">35,200</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">274,773</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee determined the Bonuses are to be paid in recognition of the past efforts of each of the
executives. The new base salaries will become effective on March&nbsp;1, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2014, the Compensation Committee also
approved the following stock option (&#147;Options&#148;) and restricted stock unit (&#147;RSUs&#148;) grants to the below executive officers pursuant to the Company&#146;s 2013 Equity Incentive Plan and the forms of Stock Option Grant Notice,
Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for officers, as filed with the Securities and Exchange Commission as exhibits to the Company&#146;s Current Report on Form 8-K on September&nbsp;23,
2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options&nbsp;Granted&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSU&#146;s&nbsp;Granted&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Bristow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">51,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56,700</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Ozeroff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, General Counsel&nbsp;&amp; Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34,200</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Wheeler</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">20,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34,200</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Vests in 48 equal monthly installments measured from February&nbsp;27, 2014 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Vests in 4 equal annual installments measured from February&nbsp;27, 2014 </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;3, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Patrick M. Wheeler</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name: Patrick M. Wheeler</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g686794g45p43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686794g45p43.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$(`M0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?F8*N2<`=Z3:6K`P+KQ9:PRE(8GF`_B!P*\6MG%*#M!<QU
MPPLI;Z$0\6Y.!8.?^!BL5G:?_+M_>5]4\P/BT*>;!_\`OL4?VVE_R[?WA]4?
M<DM_%EM)(%F@>$'^(G(%;4<YI3=IKE(GA915TS?1PZAE(*D9!'>O:335T<NP
MZF`=*`((;RWN'E2&5':)MCA3G:WH?0T`3T`037EM;%1//'%NX7>X7/TS0`AO
MK11DW4('KY@H`2+4+.<[8;J&1O1)`30!8!%``3B@"&YO;:RB,MU/'!&/XI'"
MC]:`,Q/%WAV27REUJR+^GG"@#2M[ZUNES;7,4P_Z9N&_E0!8!R*`&LX0$MP`
M,DT`1VUS#=P)-;R++$XRKH<@_C0!-0`4`8WB>9X=&8(2#(X0D>G^17EYK5E2
MP]X]78Z,-%2GJ<E:VX<@'Y?0FODJ5)3]VQZ,YZ61MP:864!DPR,-WT/>O:I8
M&Z2>ZW.65:ST%GTPKO"IDLV$^E.I@=):>@HU3%N[41DJ`"1UQTKQ:M)1TM<Z
MX3ON=/X7E9]*VLQ/EN5'L*^IRFI*IA[R>QY^)2C,W*]<YBAK.I1Z/I%SJ$S8
M6!"P'J>P_.@#R[X=ZM>:=XVO]+U0E9[_`/>N">DG4?H:`/8`:`*.I:/IVKQK
M'J%C#<JN=OF)G;GKCTH`\5\*Z#IUW\3+C2KFW$UE`\VV)V)'R],^N*`/0_%'
M@?1)=#NYK.QCLKN",R136XV,"!GMUH`S/A1XEO\`5[.ZT^_F:=K4*T<K'+;3
MV)[_`%H`V?'?C(>%M.1;=5DU"X!$2MT4=V-`&;X8\%&^BCUKQ4SZCJ$P\Q(I
MCE(0>@V],T`==/X?T:Y@,$VE6C1$8VF%?\*`.2T/PDOA3Q\SV$;?V9>VS!1R
M1$P.=I/IZ4`>@*>*`.7\=:E-::$UC9@M?ZB?L]NH/.2/F/Y4`8'PBU<S:-<:
M/*?GL&^0'^X>WX'-`'HX.10`M`&'XJ&=*0?]-5_D:\?.?]W7JOU.K"_'\C*T
MU.`&,>/1C7E8**^TT;U66IKC=J+6^<118`4&NJM6E*LZ>T491C[G,:(DARD:
M$X?@K7H*<':,7H^ABTS&U*,`,%\M5'0*:\?&*S]VR1U4F:'A;C3I/^NAKT<E
M_P!W?JS'%?&;QZ5[1RG#>+KNWU+Q)I'A^6XCBMT?[9=EW"C:OW5_$T`<G\2)
M(+#Q3IOB+3;J&5L@.(G!.Y>G3VH`];T^]CU#3[>\A.8YXPXQ[B@"UZ4`>'>'
MKY--^*^H7+PS3*))QLA3>_/L*`.KUCQ[!KD;^']!@E;4KL&'-P/*6+USGO[4
M`;?@GP=%X1TYXVE$U[/@S2`8''11[4`>=^*R=4^+D-K/@Q+-%$`>FT<T`>W!
M0.@``XH`4T`)MXQVH`.G%`'"V^H6.J_$.ZO;FZACMM'3[/`'D`W2-]YN?3I0
M!R$%W!X5^++R0W$;V%X^"T;@J%?UQZ-0![4O`H`6@#"\5\:0O_75?Y&O&SG_
M`'9>J_4ZL+\9AZ=<;&&Q5SZMVKP\)747:QUU8WW-.>WM[XB83,DP(7?CAS]*
M].I3I8AJIS6:Z]SFC*5/1K0?#'%99=YFE<$J6Q@(?I5PC3P]YREKM?L*3Y]$
MK&7J%R&8APN>S(,9]Z\O%5.9VD=-*%E<U_"A_P");)_UT->QDO\`N[MW.7%:
M3-J>X2V@DGE8+'$I=B>P`KVSE.&\&Z9;>(_[0\2ZI:1SMJ$Q\A95SLB7@8S0
M!<\8>$=.N?"M\MAIT$5U&GF1F.,*<CG%`&;\)-::]\/2Z=(W[RR?Y<GG8>GY
M'-`'HGUH`\9\'?\`)8[_`/W[C^E`&K\4?"[KL\3:<"EQ`1Y_E\'CH_U%`'4>
M!_%2>)]%5Y&5;Z#"7"CU[,/8T`<+\3M-N-&\4VGB.!"879"2.SKV/U%`'JND
MZI;ZQI=O?VKAXID#?0]P?>@"]GCWH`R-7U^'2;BPMBAEN;V811QJ<''=C["@
M!OBG61H'AR\U`\NB;8A_><\`?G0!E>%_".GV_ART_M+3X+B^E'G3/(@8[VY/
M)^M`'-?%+PS:V^C6^IZ=:16YMI-LHB4+P>AX]#0!VG@W6AKGA:RO,YE"^7+[
M.O!_QH`Z"@"GJ=DNH6+V['!/*GT/8USXFA'$4W!EPFX.Z.'FLKZQE*20/G/#
M`9!KXNKAL1AWRR7W'JQJ0FMR5+J=-@$4@"\_=-4JE5)))Z$N,7U%DNIV+_NY
M/F.3\IZTY5JDF[Q?W"48+J5X[:]O'$<,$A)]1@#\:SIX:O6E:,?O+=2$%>YV
MVEV`TZQ2`'+=6/J:^RPF'CAJ:A$\NI/GE<Q/$N@:YX@BGL8]5AL].DX(2,F1
MAZ$YZ5UF9-X8T75M!M8=/N+VWN;"!"L96,JX],]J`-'5X=6F@5-+GMX&.0[3
MH6XQV`H`X;2OAGJ^AWXU#3_$*I<\[@8?E<$Y((STH`["XM_$CZ?"D%Y8QW?/
MFR&)BOL5&:`.0L/AIJVEZO\`VO:^(4-^69F9X,AMW4'F@#O+2WNY-.,.K&":
M5\K)Y2D(RGM@T`<-8?#74-%UJ:^T;71:(6/EQF+<-O\`=;U%`':1:=/?:2]G
MKRVUV9"0PC0A2.W![T`<Q9^!]5\-7<DOAK6`MM(<M9W:ED_`CD4`:S/XRE0H
MMOI=NQ'^L+L^/PQ0!G:7X'OH/$T>OZKK1OKM%8!/+PJDCMZ"@"+Q!X-U[Q-)
M$;W7(88H7WQPPPG;D="<GDT`=3I4.JPVY35)[>:12`C0H5X]\]Z`,OQ/H>L:
M]:SZ=!?6UO83J%?=$6D]_:@#%T#P-KWA=W_LS7HI(9#F2&:'Y2?48/!H`[VW
M$HMHA<%3,$&\H,`MCG'MF@"3%`#2H/:E8`VCT%,`VCT%``%`[4`*!B@#.UB]
MEL;`RP[3*S!$##.2:`+D&]8D$K!I,#<1ZT`1N]W]NC5$C-KM.]B?F![8%`%C
M<!@=*`$9@!DG`'-`$5K=PW=N)H'WQDX!Q0!2U>\N+8VD=J4\R>4)AAGCN10!
MI`@8QS[T`+N`&:``,#TZ>M`!N%`!N%`!N%`!N%`!N&<=Z`%!S0`M`!0`4`%`
M!0`4`)S]*`.?U%OMNM)"9/+MK)?-E;W/0"@"QH\)AL[B9MT<4KET#')1?7G\
MZ`(M!`FENKTNQ\TX4$Y.P=S]:`,^XG>YTZZO96)GEE\FTC!^[@XX]Z`-37)9
M8=%6(2$7,I6)=IQECUH`KV5JMKXA2WM`5A@MML^#P6/3\:`'3(=0\1D>9LM[
M),,V<98]0/PH`=I)6SL+V\8L+5I&>-3V0>GUH`IWUR;N.&!Y2)[HABH;"PQ_
MXT`7]>Q!HXBA)!;$4:`_>)Z4`6+#2TM?*FD=WN%CV,Q8X_*@#&GE#7UY?M*Y
MM;=3$,-_K7/\(]J`([:U9)+"RFF(E1O.D^8XC!Z*/<T`;E_>%;E;1)!$2ADE
MD/\``@]/>@"IH:I=7ES?`G:WR0JQ)(0=_P`:`-X#%`"T`%`!0`4`%`!0`A%`
M%1],M)+LW+P*9>,L>_U%`%B2)98FCD4%&&"/44`-M[:*UA6*"-8T7H!VH`B3
M3K6.X,ZPJ),D@^A/4@=J`*=W8S7VKV_G0G['`A;)8?,Y^AS0!H06L5M'LA0*
M,Y/<D^_K0!#)I=G(I#6ZG,GF'W;UH`L2P1RP-`Z`QL-I7MB@"M'I-E$T3);(
M&B&$]J`+#VT4CQO(@9HSE"?X30!*5!4C'!ZT`51IUHL4<0MT\N-MZKV#>M`#
MEL;=+M[H0KY[C!?O0`DVGVL]P+B6!7E`VACZ4`.M;."RC$5O$L:#L*`+%`!0
K`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
